CPSE:NOVO BPharmaceuticals
Wegovy Pill Reaches UAE As Novo Nordisk Expands Obesity Market Reach
Novo Nordisk (CPSE:NOVO B) has launched its oral Wegovy pill in the United Arab Emirates, the first country outside the U.S. to offer this obesity treatment.
The company has received positive regulatory recommendations in the EU for the Wegovy pill and for a higher dose injectable version.
These approvals expand access to obesity therapies for patients who may prefer pills over injections and widen the potential user base for Novo Nordisk’s obesity portfolio.
Novo Nordisk, best known for...